16 results
8-K
EX-99.1
PLX
Protalix BioTherapeutics Inc.
14 Mar 24
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
6:57am
training expenses.
Financial expense, net was $1.9 million for the year ended December 31, 2023, an increase of $0.5 million, or 36%, compared
8-K/A
EX-10.6
6eiq8
20 Sep 07
Financial Statements and Exhibits
12:00am
8-K
EX-10.6
14prork4df6oapa
8 Jan 07
Entry into a Material Definitive Agreement
12:00am
8-K
3qvi6jf 4wml4w
8 Jan 07
Entry into a Material Definitive Agreement
12:00am
424B3
lnn934 5phmlemp
30 Mar 98
Prospectus supplement
12:00am
S-4
nsa6k 4xt
26 Mar 98
Registration of securities issued in business combination transactions
12:00am
- Prev
- 1
- Next